These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31505986)

  • 61. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measurement error in continuous endpoints in randomised trials: Problems and solutions.
    Nab L; Groenwold RHH; Welsing PMJ; van Smeden M
    Stat Med; 2019 Nov; 38(27):5182-5196. PubMed ID: 31478240
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Equivalence testing with dental clinical trials.
    Burns DR; Elswick RK
    J Dent Res; 2001 Jun; 80(6):1513-7. PubMed ID: 11499504
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A multistage analysis strategy for a clinical trial to assess successively more stringent criteria for a primary endpoint with a low event rate.
    Li S; Hussey MA; Schwartz TA; Koch GG
    Pharm Stat; 2013; 12(2):65-73. PubMed ID: 23424092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Generic immunosuppressants.
    Medeiros M; Lumini J; Stern N; Castañeda-Hernández G; Filler G
    Pediatr Nephrol; 2018 Jul; 33(7):1123-1131. PubMed ID: 28733752
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sample size determination for individual bioequivalence inference.
    Chiang C; Hsiao CF; Liu JP
    PLoS One; 2014; 9(10):e109746. PubMed ID: 25310592
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial.
    Alemayehu C; Mitchell G; Aseffa A; Clavarino A; McGree J; Nikles J
    Trials; 2017 Oct; 18(1):470. PubMed ID: 29017595
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
    Mayer-Hamblett N; Kronmal RA
    Contemp Clin Trials; 2005 Feb; 26(1):2-16. PubMed ID: 15837448
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
    Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
    JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reducing sample size by combining superiority and non-inferiority for two primary endpoints in the Social Fitness study.
    Donkers H; Graff M; Vernooij-Dassen M; Nijhuis-van der Sanden M; Teerenstra S
    J Clin Epidemiol; 2017 Jan; 81():86-95. PubMed ID: 27650383
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Statistical considerations for noninferiority/equivalence trials in vaccine development.
    Wang WW; Mehrotra DV; Chan IS; Heyse JF
    J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
    Hothorn LA; Wassmer G
    J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The bootstrap procedure in individual bioequivalence.
    Shao J; Chow SC; Wang B
    Stat Med; 2000 Oct; 19(20):2741-54. PubMed ID: 11033572
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.